Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATE: Reduced anticoagulation targets in extracorporeal life support
2023-509675-16-01Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of heparin and nadroparin in respiratory failure and heart failure (HF) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Primary composite outcome. Planned start Jan 2025; status: authorised.
02
Drugs
heparinnadroparin
03
Conditions
respiratory failureheart failure (HF)
Beyond the preview
Go deeper on 2023-509675-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509675-16-01.